Sutro Biopharma (STRO) announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023. Prior to joining Sutro, Dr. Borgman served as Vice President and Therapeutic Area Lead, Oncology, Hematology, and Transplant, at Jazz Pharmaceuticals (JAZZ), where she was responsible for global drug development for four marketed products and drug development plans for several emerging targets.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on STRO:
- Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
- Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sutro Biopharma price target raised to $25 from $21 at Truist
- Sutro Biopharma price target raised to $18 from $16 at Piper Sandler
- Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
